Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more
Appili Therapeutics Inc (APLIF) - Total Liabilities
Latest total liabilities as of September 2025: $16.36 Million USD
Based on the latest financial reports, Appili Therapeutics Inc (APLIF) has total liabilities worth $16.36 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Appili Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Appili Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Appili Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Appili Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EITZEN CHEMICALS
F:E8H
|
Germany | €3.76 Million |
|
Welltower OP LLC
STU:HCW
|
Germany | €15.85 Billion |
|
Valhalla Metals Inc.
OTCQB:VMXXF
|
USA | $413.30K |
|
Reflect Scientific Inc
OTCQB:RSCF
|
USA | $258.55K |
|
Revelation Biosciences Inc
NASDAQ:REVB
|
USA | $1.85 Million |
|
AMETEK
BE:AK1
|
Germany | €5.22 Billion |
|
Franklin Mining Inc
PINK:FMNJ
|
USA | $-259.12K |
Liability Composition Analysis (2017–2025)
This chart breaks down Appili Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 21.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Appili Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Appili Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Appili Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $16.43 Million | +32.34% |
| 2024-03-31 | $12.42 Million | +7.47% |
| 2023-03-31 | $11.55 Million | +107.62% |
| 2022-03-31 | $5.56 Million | +138.96% |
| 2021-03-31 | $2.33 Million | -3.59% |
| 2020-03-31 | $2.42 Million | 0.00% |
| 2019-03-31 | $2.42 Million | +3.95% |
| 2018-03-31 | $2.32 Million | +94.78% |
| 2017-03-31 | $1.19 Million | -- |